Dashboard
Manage Tickers

CANFCan-Fite BioPharma Ltd.

NYSE canfite.com


$ 2.39 $ 0.00 (0 %)    

Friday, 05-Jul-2024 14:31:36 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 495.74 $ 4.00 (0.81 %)
DIA $ 393.33 $ 0.69 (0.18 %)
SPY $ 554.12 $ 2.33 (0.42 %)
TLT $ 92.57 $ 0.49 (0.53 %)
GLD $ 220.96 $ 1.45 (0.66 %)
$ 2.42
$ 2.39
$ 0.00 x 0
$ 2.44 x 150
$ 2.39 - $ 2.39
$ 1.81 - $ 4.48
21,732
na
3.29B
$ 0.72
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

can-fite-biopharma-announced-that-a-patient-with-liver-decompensated-cirrhosis-who-was-treated-with-namodenoson-at-the-soroka-medical-center-in-israel-under-compassionate-use-showed-an-improvement-in-liver-indices
Can-Fite Biopharma Announced That A Patien...
07/01/2024 11:10:17

This Drug Candidate Is Currently Used In A Pivotal Phase 3 Study For Patients With Advanced Liver Cancer And A Phase 2b Study F...

can-fite-biopharma-says-its-veterinary-partner-vetbiolix-reported-positive-results-in-an-osteoarthritis-multicenter-clinical-study-in-dogs-treated-with-piclidenoson
Can-fite Biopharma Says Its Veterinary Par...
06/28/2024 11:07:27

can-fite-announces-new-findings-on-namodenosons-dual-anti-cancer-and-liver-protective-effects
Can-Fite Announces New Findings on Namoden...
06/24/2024 11:04:22

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule dr...

12-health-care-stocks-moving-in-fridays-after-market-session
12 Health Care Stocks Moving In Friday's A...
06/14/2024 20:31:12

why-ammo-shares-are-trading-lower-by-over-19-here-are-other-stocks-moving-in-fridays-mid-day-session
Why AMMO Shares Are Trading Lower By Over ...
06/14/2024 18:13:08

can-fite-biopharma-says-its-phase-3-study-for-namodenoson-for-advanced-liver-cancer-is-31-recruiting-medical-centers-namodenoson-has-orphan-drug-status-from-fda-and-european-medicines-agency-and-fda-fast-track-status
Can-Fite Biopharma Says Its Phase 3 Study ...
06/05/2024 11:18:20

A compassionate use program has also been ongoing in Israel and Romania. 

hc-wainwright--co-reiterates-buy-on-can-fite-biofarma-maintains-18-price-target
HC Wainwright & Co. Reiterates Buy on Can ...
05/09/2024 17:47:26

HC Wainwright & Co. analyst Vernon Bernardino reiterates Can Fite Biofarma (AMEX:CANF) with a Buy and maintains $18 pric...

the-fda-has-granted-investigational-new-drug-clearance-for-can-fite-biopharmas-namodenoson-for-metabolic-dysfunction-associated-steatohepatitis-also-known-as-non-alcoholic-steatohepatitis-for-the-companys-ongoing-phase-2b-study
The FDA Has Granted Investigational New Dr...
05/09/2024 12:21:58

can-fite-received-notice-of-allowance-from-the-european-patent-office-for-the-treatment-of-erectile-dysfunction-with-cf602
Can-Fite Received Notice of Allowance from...
05/06/2024 11:04:23

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule dru...

12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's...
04/25/2024 12:06:47

can-fite-biopharma-announced-it-published-an-article-in-the-experimental-and-therapeutic-medicine-journal-long-term-complete-response-to-namodenoson-in-liver-cancer-with-child-pugh-b-cirrhosis
Can-Fite Biopharma Announced It Published ...
04/25/2024 11:28:46

The Patient Participated In The Phase Ii Liver Cancer Study And Has Been Treated With Namodenoson For >7 Years Under Compass...

can-fites-namodenoson-featured-in-biomedicines-for-liver-cancer-and-mash-treatment-insights
Can-Fite's Namodenoson Featured in Biomedi...
04/15/2024 11:06:38

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule dr...

can-fite-biopharma-submits-fda-with-an-ind-application-to-conduct-phase-iib-clinical-trial-of-namodenoson-in-mash-patients
Can-Fite BioPharma Submits FDA with an IND...
04/03/2024 11:03:06

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule dru...

can-fite-biofarma-q4-earnings-insights
Can Fite Biofarma: Q4 Earnings Insights
03/28/2024 11:50:05

can-fite-biofarma-fy-gaap-eps-001-same-yoy-sales-74300k-down-from-81000k-yoy
Can Fite Biofarma FY GAAP EPS $(0.01), Sam...
03/28/2024 11:23:54

Can Fite Biofarma (AMEX:CANF) reported quarterly losses of $(0.01) per share. This is unchanged from the same period last year....

can-fite-biopharma-announced-notice-of-allowance-in-canada-for-its-patent-application-regarding-se-of-namodenoson-for-the-reduction-of-liver-fat-in-patients-with-nash
Can-Fite BioPharma Announced Notice Of All...
02/28/2024 12:12:11

can-fite-expands-the-out-licensing-deal-with-ewopharma-to-include-the-pancreatic-cancer-indication
Can-Fite Expands the Out-Licensing Deal wi...
01/30/2024 12:03:19

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule dru...

can-fites-latest-innovation-namodenoson-shows-significant-results-in-obesity-reduction
Can-Fite's Latest Innovation: Namodenoson ...
12/20/2023 12:07:16

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule dr...

can-fite-receives-positive-response-from-fda-on-pediatric-study-plan-for-treatment-of-children-suffering-from-psoriasis-with-piclidenoson
Can-Fite Receives Positive Response From F...
12/18/2023 12:05:11

The plan has been submitted to allow enrollment of children with psoriasis to Can-Fite's upcoming Phase 3 pivotal clinical ...

can-fite-biopharma-has-completed-the-design-of-phase-2a-study-protocol-for-pancreatic-cancer-and-plans-to-submit-the-protocol-shortly-to-ethical-committees-for-approval-study-will-aim-to-enroll-about-20-patients-to-establish-safety-and-clinical-activity
Can-Fite Biopharma Has Completed The Desig...
12/04/2023 12:09:58

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)
07/16/2024 Vestis Corporation (VSTS)
07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)